Liver Diseases  >>  Daklinza (daclatasvir)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Daklinza (daclatasvir) / BMS
NCT01389323: BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

Completed
3
448
US
Daclatasvir, BMS-790052, Peg-Interferon Alfa-2a, Pegasys, Ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C
09/13
01/14
NCT01448044 / 2011-002793-23: Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Completed
3
152
US, Europe
BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Pegasys, Ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C
10/13
01/14
COMMAND-3, NCT01492426 / 2011-004237-14: Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

Checkmark VHC 2014: COMMAND-3
Oct 2014 - Oct 2014: VHC 2014: COMMAND-3
Completed
3
605
US, Canada, Europe, RoW
Daclatasvir, BMS-790052, Telaprevir, Incivek®, Peginterferon alfa-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C
12/13
03/14
NCT01471574 / 2011-003067-30: Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Completed
3
549
US, Canada, Europe, RoW
Daclatasvir, BMS-790052, Ribavirin, Copegus®, PEG-Interferon alfa 2a, Pegasys®, Pegylated interferon
Bristol-Myers Squibb
Hepatitis C, Genotype 1
06/14
09/14
PRINCIPAL, NCT01616524 / 2011-004885-14: Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

Completed
3
880
Japan, US, Europe, RoW
Pegylated interferon lambda (pegIFNλ), BMS-914143, Pegylated interferon alfa-2a (pegIFNα-2a), Pegasys, Ribavirin, Ribasphere, Daclatasvir, BMS-790052, Placebo matching Daclatasvir
Bristol-Myers Squibb
Hepatitis C Virus (HCV)
06/14
09/14
NCT01718158 / 2011-005409-65: Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

Completed
3
444
Japan, US, Europe, RoW
Peginterferon Lambda-1a, BMS-914143, Peginterferon Alfa-2a, Pegasys®, Ribavirin, Copegus®, Daclatasvir, BMS-790052, Telaprevir, Incivek®
Bristol-Myers Squibb
Hepatitis C
10/14
10/14
DIMENSION, NCT01866930 / 2012-003280-22: Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV

Terminated
3
453
Europe, Canada, US, RoW
Pegylated Interferon Lambda-1a, BMS-914143, Daclatasvir (DCV), BMS-790052, Ribasphere (RBV)
Bristol-Myers Squibb
Chronic Hepatitis C Infection
08/15
08/15
COMMAND-Asia, NCT01797848: Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients

Withdrawn
3
0
RoW
Peginterferon alfa 2a, Pegasys®, Ribavirin, Copegus® (Taiwan, Korea and Singapore), Wei Lining (China), Placebo matching Daclatasvir, Daclatasvir, BMS-790052-05
Bristol-Myers Squibb
Hepatitis C
11/16
11/16

Download Options